Nazanin Zamani-Siahkali MD , Seyed Ali Mirshahvalad MD, MPH, FEBNM , Abolfazl Farbod MD , Ghasemali Divband MD , Christian Pirich MD, PHD , Patrick Veit-Haibach MD , Gary Cook MBBS, MSC, MD , Mohsen Beheshti MD
{"title":"用于骨转移瘤反应评估的 SPECT/CT、PET/CT 和 PET/MRI。","authors":"Nazanin Zamani-Siahkali MD , Seyed Ali Mirshahvalad MD, MPH, FEBNM , Abolfazl Farbod MD , Ghasemali Divband MD , Christian Pirich MD, PHD , Patrick Veit-Haibach MD , Gary Cook MBBS, MSC, MD , Mohsen Beheshti MD","doi":"10.1053/j.semnuclmed.2023.11.005","DOIUrl":null,"url":null,"abstract":"<div><p>Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [<sup>18</sup>F]F-FDG and [<sup>18</sup>F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [<sup>99m</sup>Tc]Tc-PSMA, [<sup>68</sup>Ga]Ga-PSMA, or [<sup>11</sup>C]C- or [<sup>18</sup>F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.</p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 3","pages":"Pages 356-370"},"PeriodicalIF":4.6000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0001299823000934/pdfft?md5=9796e6c2a1b1c88d7454288527f3bf6f&pid=1-s2.0-S0001299823000934-main.pdf","citationCount":"0","resultStr":"{\"title\":\"SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases\",\"authors\":\"Nazanin Zamani-Siahkali MD , Seyed Ali Mirshahvalad MD, MPH, FEBNM , Abolfazl Farbod MD , Ghasemali Divband MD , Christian Pirich MD, PHD , Patrick Veit-Haibach MD , Gary Cook MBBS, MSC, MD , Mohsen Beheshti MD\",\"doi\":\"10.1053/j.semnuclmed.2023.11.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [<sup>18</sup>F]F-FDG and [<sup>18</sup>F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [<sup>99m</sup>Tc]Tc-PSMA, [<sup>68</sup>Ga]Ga-PSMA, or [<sup>11</sup>C]C- or [<sup>18</sup>F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.</p></div>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":\"54 3\",\"pages\":\"Pages 356-370\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0001299823000934/pdfft?md5=9796e6c2a1b1c88d7454288527f3bf6f&pid=1-s2.0-S0001299823000934-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001299823000934\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299823000934","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases
Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [18F]F-FDG and [18F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [99mTc]Tc-PSMA, [68Ga]Ga-PSMA, or [11C]C- or [18F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.
期刊介绍：
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
